Management Uptake / Adherence
~ Genetics of Breast & Ovarian Cancer

References concerning the statistics, counts or trends of those choosing various management options

List was last updated on Jun 23, 2020 @ 3:52 pm.


    • Machine learning-based lifetime breast cancer risk reclassification compared with the BOADICEA model: impact on screening recommendations.
    • Ming C, Viassolo V, Probst-Hensch N, Dinov ID, Chappuis PO, Katapodi MC.
    • Br J Cancer. 2020 Jun 22. doi: 10.1038/s41416-020-0937-0. Epub ahead of print.
    • Improving primary care identification of familial breast cancer risk using proactive invitation and decision support.
    • Qureshi N, Dutton B, Weng S, Sheehan C, Chorley W, Robertson JFR, Kendrick D, Kai J.
    • Fam Cancer. 2020 Jun 11. doi: 10.1007/s10689-020-00188-z. Epub ahead of print.
    • Utilization of Complementary Alternative Medicine, Diet, and Exercise Among Women at High Risk for Developing Breast Cancer.
    • Lee RT, Amico A, Malaka D, Lewin R, Cummings SA, Verp M, Patrick-Miller L, Bradbury AR, Olopade OI.
    • Integr Cancer Ther. 2020 Jan-Dec;19:1534735420922610. doi: 10.1177/1534735420922610. [First Published 2020 May 23.]
    • Factors associated with counseling and postoperative hormone therapy use in surgically menopausal women.
    • Verrilli L, Brown H, Williams M.
    • Menopause. 2020 May 11. doi: 10.1097/GME.0000000000001560. Epub ahead of print.
    • Comparison of mammography behaviors, health beliefs, and fear levels of women with and without familial breast cancer history.
    • Erdogan E, Tuzcu A.
    • Women Health. 2020 Apr 6:1-16. doi: 10.1080/03630242.2020.1746949. [Epub ahead of print]
    • Longitudinal outcomes with cancer multigene panel testing in previously tested BRCA1/2 negative patients.
    • Bradbury AR, Egleston BL, Patrick-Miller LJ, Rustgi N, Brandt A, Brower J, DiGiovanni L, Fetzer D, Berkelbach C, Long JM, Powers J, Stopfer JE, Domchek SM.
    • Clin Genet. 2020 Apr;97(4):601-609. doi: 10.1111/cge.13716.
    • Does Medicare-eligible high-risk breast cancer screening MRI target the right women?
    • Lo G, McLaughlin A, Jacques A, Dhillon R, Porter G, Jayaratne T, Bose S, Bourke A.
    • J Med Imaging Radiat Oncol. 2020 Apr;64(2):220-228. doi: 10.1111/1754-9485.13009. Epub 2020 Feb 9.
    • Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience.
    • Vriens IJH, Ter Welle-Butalid EM, de Boer M, de Die-Smulders CEM, Derhaag JG, Geurts SME, van Hellemond IEG, Luiten EJT, Dercksen MW, Lemaire BMD, van Haaren ERM, Vriens BEPJ, van de Wouw AJ, van Riel AMGH, Janssen-Engelen SLE, van de Poel MHW, Schepers-van der Sterren EEM, van Golde RJT, Tjan-Heijnen VCG.
    • Breast Cancer Res Treat. 2020 Mar 31. doi: 10.1007/s10549-020-05598-2. [Epub ahead of print]

    Related:

    Letter:

    Fertility and reproduction in breast cancer patients.

    • Uptake of Risk Appropriate Behaviors After Breast Cancer Risk Stratification in the Mammography Screening Population.
    • Conley CC, Niell BL, Augusto BM, McIntyre M, Roetzheim R, Funaro K, Vadaparampil ST.
    • J Am Coll Radiol. 2020 Mar 27. pii: S1546-1440(20)30240-4. doi: 10.1016/j.jacr.2020.02.019. [Epub ahead of print]

    Related:

    Press: Mailed Notices of High Breast Cancer Risk Do Not Often Translate Into Behavior Changes. (Medscape/Reuters)

    • Hormone Replacement Therapy Prescription After Premature Surgical Menopause.
    • Garg N, Behbehani S, Kosiorek H, Wasson M.
    • J Minim Invasive Gynecol. 2020 Mar 12. pii: S1553-4650(20)30124-2. doi: 10.1016/j.jmig.2020.03.002. [Epub ahead of print]
    • Feasibility, patient compliance and acceptability of ovarian cancer surveillance using two serum biomarkers and Risk of Ovarian Cancer Algorithm compared to standard ultrasound and CA 125 among women with BRCA mutations.
    • Haque R, Skates SJ, Armstrong MA, Lentz SE, Anderson M, Jiang W, Alvarado MM, Chillemi G, Shaw SF, Kushi LH, Powell CB.
    • Gynecol Oncol. 2020 Mar 4. pii: S0090-8258(20)30164-5. doi: 10.1016/j.ygyno.2020.02.027. [Epub ahead of print]
    • Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers?
    • Mills KA, Joshi TV, West L, Kuznicki M, Kent L, Hokenstad AN, Cripe JC, Woolfolk C, Senter L, Bakkum-Gamez JN, Wenham RM, Cohn DE, Bae-Jump V, Thaker PH.
    • Gynecol Oncol. 2020 Mar 3. pii: S0090-8258(20)30179-7. doi: 10.1016/j.ygyno.2020.02.033. [Epub ahead of print]
    • Factors that impact risk management decisions among women with pathogenic variants in moderate penetrance genes associated with hereditary breast cancer.
    • Napoli M, Lewis J, Hopper J, Widmeyer K.
    • J Genet Couns. 2020 Feb 3. doi: 10.1002/jgc4.1220. [Epub ahead of print]
    • Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program.
    • Hao J, Hassen D, Manickam K, Murray MF, Hartzel DN, Hu Y, Liu K, Rahm AK, Williams MS, Lazzeri A, Buchanan A, Sturm A, Snyder SR.
    • J Pers Med. 2020 Feb 3;10(1). pii: E7. doi: 10.3390/jpm10010007.
    • Radiographic Surveillance of Patients with Non-BRCA1/2 Pathogenic Variants.
    • Hudson L, Gower N, Lenarcic S, Trufan SJ, White RL Jr.
    • Ann Surg Oncol. 2020 Jan 23. doi: 10.1245/s10434-019-08191-0. [Epub ahead of print]
    • Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling.
    • Frey MK, Kahn RM, Chapman-Davis E, Tubito F, Pires , Christos P, Anderson S, Mukherjee S, Jordan B, Blank , Caputo TA, Sharaf , Offit K, Holcomb K, Lipkin S.
    • J Clin Oncol. 2020 Jan 10:JCO1902005. doi: 10.1200/JCO.19.02005. [Epub ahead of print]
    • Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients.
    • Tynan M, Peshkin BN, Isaacs C, Willey S, Valdimarsdottir HB, Nusbaum R, Hooker G, O'Neill SC, Jandorf L, Kelly SP, Heinzmann J, Kelleher S, Poggi E, Schwartz MD.
    • Breast Cancer Res Treat. 2020 Jan 1. doi: 10.1007/s10549-019-05515-2. [Epub ahead of print]
    • Cancer Prevention in Primary Care: Perception of Importance, Recognition of Risk Factors and Prescribing Behaviors.
    • Samimi G, Heckman-Stoddard BM, Holmberg C, Tennant B, Sheppard BB, Coa KI, Kay SS, Ford LG, Szabo E, Minasian LM.
    • Am J Med. 2019 Dec 17. pii: S0002-9343(19)31095-2. doi: 10.1016/j.amjmed.2019.11.017. [Epub ahead of print]
    • Increased Overall Mortality Even after Risk Reducing Surgery for BRCA-Positive Women in Western Sweden.
    • Öfverholm A, Einbeigi Z, Wigermo A, Holmberg E, Karsson P.
    • Genes (Basel). 2019 Dec 16;10(12). pii: E1046. doi: 10.3390/genes10121046.
    • Sporadic implementation of UK familial mammographic surveillance guidelines 15 years after original publication.
    • Evans DG, Edwards M, Duffy SW; Cancer Genetics Group clinical leads, Tischkowitz M.
    • Br J Cancer. 2019 Nov 25. doi: 10.1038/s41416-019-0631-2. [Epub ahead of print]
    • Counseling young women with early breast cancer on fertility preservation.
    • Ter Welle-Butalid MEE, Vriens IJHI, Derhaag JGJ, Leter EME, de Die-Smulders CEC, Smidt MM, van Golde RJTR, Tjan-Heijnen VCGV.
    • J Assist Reprod Genet. 2019 Nov 23. doi: 10.1007/s10815-019-01615-6. [Epub ahead of print]
    • Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    • Vysotskaia V, Kaseniit KE, Bucheit L, Ready K, Price K, Johansen Taber K.
    • Cancer. 2019 Nov 4. doi: 10.1002/cncr.32572. [Epub ahead of print]
    • Impact of Genetic Testing on Risk-Management Behavior of Black Breast Cancer Survivors: A Longitudinal, Observational Study.
    • Conley CC, Kasting ML, Augusto BM, Garcia JD, Cragun D, Gonzalez BD, Kim J, Ashing KT, Knott CL, Hughes-Halbert C, Pal T, Vadaparampil ST.
    • Ann Surg Oncol. 2019 Nov 1. doi: 10.1245/s10434-019-07982-9. [Epub ahead of print]
    • Outcomes of women at high familial risk for breast cancer: An 8-year single-center experience.
    • Lammert J, Skandarajah AR, Shackleton K, Calder P, Thomas S, Lindeman GJ, Mann GB.
    • Asia Pac J Clin Oncol. 2019 Oct 28. doi: 10.1111/ajco.13274. [Epub ahead of print]
    • All For BRCA, BRCA For All?
    • Resta R.
    • The DNA Exchange. 2019 Oct 7.
    • A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy.
    • Gronwald J, Lubinski J, Huzarski T, Cybulski C, Menkiszak J, Siołek M, Stawicka M, Sun P, Kim S, Kotsopoulos J, Narod SA.
    • Gynecol Oncol. 2019 Sep 6. pii: S0090-8258(19)31486-6. doi: 10.1016/j.ygyno.2019.08.034. [Epub ahead of print]
    • Patient-physician relationships, health self-efficacy, and gynecologic cancer screening among women with Lynch syndrome.
    • McGarragle KM, Aronson M, Semotiuk K, Holter S, Hare CJ, Ferguson SE, Cohen Z, Hart TL.
    • Hered Cancer Clin Pract. 2019 Aug 13;17:24. doi: 10.1186/s13053-019-0123-7. eCollection 2019.
    • Participation in a Novel Trial Assessing Prophylactic Breast Irradiation: The Importance of Input from the Radiation Oncologist.
    • Evron E, Goldberg H, Ben-David MA, Corn BW.
    • Int J Radiat Oncol Biol Phys. 2019 Aug 10. pii: S0360-3016(19)33636-3. doi: 10.1016/j.ijrobp.2019.08.004. [Epub ahead of print]
    • Impact of genetic counseling on the uptake of contralateral prophylactic mastectomy among younger women with breast cancer.
    • Terkelsen T, Rønning H, Skytte AB.
    • Acta Oncol. 2019 Aug 5:1-6. doi: 10.1080/0284186X.2019.1648860. [Epub ahead of print]
    • Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.
    • van den Broek AJ, Schmidt MK, van 't Veer LJ, Oldenburg HSA, Rutgers EJ, Russell NS, Smit VTHBM, Voogd AC, Koppert LB, Siesling S, Jobsen JJ, Westenend PJ, van Leeuwen FE, Tollenaar RAEM.
    • Ann Surg. 2019 Aug;270(2):364-372. doi: 10.1097/SLA.0000000000002804.
    • A Microsimulation Model for Evaluating the Effectiveness of Cancer Risk Management for BRCA Pathogenic Variant Carriers: miBRovaCAre.
    • Petelin L, Hossack L, Mitchell G, Liew D, Trainer AH, James PA.
    • Value Health. 2019 Aug;22(8):854-862. doi: 10.1016/j.jval.2019.03.008. Epub 2019 May 17.
    • Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
    • Chang J, Seng S, Yoo J, Equivel P, Lum SS.
    • Ann Surg Oncol. 2019 Jul 24. doi: 10.1245/s10434-019-07595-2. [Epub ahead of print]
    • Breast reconstruction after risk-reducing mastectomy in BRCA mutation carriers.
    • Nagura N, Hayashi N, Takei J, Yoshida A, Ochi T, Iwahira Y, Yamauchi H.
    • Breast Cancer. 2019 Jul 10. doi: 10.1007/s12282-019-00995-y. [Epub ahead of print]
    • Barriers to the utilization of genetic testing and genetic counseling in patients with suspected hereditary breast and ovarian cancers.
    • Swink A, Nair A, Hoof P, Matthews A, Burden C, Johnson K, Blum JL.
    • Proc (Bayl Univ Med Cent). 2019 Jun 11;32(3):340-344. doi: 10.1080/08998280.2019.1612702. eCollection 2019 Jul.
    • Concurrent hysterectomy at the tine of risk-reducing surgery for patients with BRCA mutations.
    • Gordhandas S, Ruiz MP, Talukdar N, Holcomb KM, Freya MK, Chapman-Davis E, Kahn RM.
    • Gynecol Oncol. 2019 Jun;153(3):e12-e13. doi: 10.1016/j.ygyno.2019.03.134.
    • Conference abstract
    • Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations.
    • Salyer C, Kobelka C, Barrie A, Weintraub MR, Powell CB.
    • Gynecol Oncol. 2019 May 31. pii: S0090-8258(19)31261-2. doi: 10.1016/j.ygyno.2019.05.017. [Epub ahead of print]
    • Challenges in Managing Patients with Hereditary Cancer at Gynecological Services.
    • Ueda M, Tsubamoto H, Kashima-Morii M, Torii Y, Kamihigashi M, Wakimoto Y, Nakagomi N, Hashimoto-Tamaoki T, Sawai H, Shibahara H.
    • Obstet Gynecol Int. 2019 May 27;2019:4365754. doi: 10.1155/2019/4365754. eCollection 2019.
    • NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program.
    • Maani N, Westergard S, Yang J, Scaranelo AM, Telesca S, Thain E, Schachter NF, McCuaig JM, Kim RH.
    • Cancers (Basel). 2019 May 22;11(5). pii: E707. doi: 10.3390/cancers11050707.
    • Effectiveness of interventions to identify and manage patients with familial cancer risk in primary care: a systematic review.
    • Lee SI, Patel M, Dutton B, Weng S, Luveta J, Qureshi N.
    • J Community Genet. 2019 May 6. doi: 10.1007/s12687-019-00419-6. [Epub ahead of print]
    • Review
    • Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma?
    • Roch AM, Schneider J, Carr RA, Lancaster WP, House MG, Zyromski NJ, Nakeeb A, Schmidt CM, Ceppa EP.
    • J Surg Oncol. 2019 May;119(6):777-783. doi: 10.1002/jso.25376. Epub 2019 Jan 12.
    • Hereditary Breast Cancer Risk Analysis in Uninsured Mexican-Origin Women Living in the U.S.-Mexico Border Region.
    • Salinas JJ, Roy R, Dwivedi AK, Shokar NK.
    • Hisp Health Care Int. 2019 Apr 12:1540415319837850. doi: 10.1177/1540415319837850. [Epub ahead of print]
    • International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.
    • Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, Pal T, Lynch HT, Tung NM, Kwong A, Ainsworth P, Karlan B, Moller P, Eng C, Weitzel JN, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • Br J Cancer. 2019 Apr 11. doi: 10.1038/s41416-019-0446-1. [Epub ahead of print]

    Related:

    Editorial:

    Cancer screening and prevention in BRCA mutation carriers: a missed opportunity?

    • Predictive Power of PEN-3 Model Constructs in Breast Cancer Screening Behaviors among Teachers: A Cross- Sectional Study in Central Iran.
    • Moghaddam ES, Shahnazi H, Hassanzadeh A.
    • Eur J Breast Health. 2019 Apr 1;15(2):105-110. doi: 10.5152/ejbh.2019.4417. eCollection 2019 Apr.
    • Evolving indications and long-term oncological outcomes of risk-reducing bilateral nipple-sparing mastectomy.
    • Grobmyer SR, Pederson HJ, Valente SA, Al-Hilli Z, Radford D, Djohan R, Yetman R, Eng C, Crowe JP.
    • BJS Open. 2018 Nov 26;3(2):169-173. doi: 10.1002/bjs5.50117. eCollection 2019 Apr.
    • Yield of surveillance magnetic resonance imaging after bilateral mastectomy and reconstruction: a retrospective cohort study.
    • Golan O, Amitai Y, Barnea Y, Menes TS.
    • Breast Cancer Res Treat. 2019 Apr;174(2):463-468. doi: 10.1007/s10549-018-05077-9. Epub 2018 Dec 3.
    • A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
    • Donenberg T, George S, Ali J, Bravo G, Hernandez K, Sookar N, Ashing KT, Narod SA, Akbari MR, Hurley J.
    • Breast Cancer Res Treat. 2019 Apr;174(2):469-477. doi: 10.1007/s10549-018-5045-y. Epub 2018 Dec 4.
    • Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility.
    • Rowley SM, Mascarenhas L, Devereux L, Li N, Amarasinghe KC, Zethoven M, Lee JEA, Lewis A, Morgan JA, Limb S, Young MA, James PA, Trainer AH, Campbell IG.
    • Genet Med. 2019 Apr;21(4):913-922. doi: 10.1038/s41436-018-0277-0. Epub 2018 Sep 26.
    • Risk perception and screening behavior of Filipino women at risk for breast cancer: implications for cancer genetic counseling.
    • Lagarde JBB, Laurino MY, San Juan MD, Cauyan JML, Tumulak MJR, Ventura ER.
    • J Community Genet. 2019 Apr;10(2):281-289. doi: 10.1007/s12687-018-0391-3. Epub 2018 Sep 27.
    • Gaps in information about breast cancer risk and prevention impact African American women.
    • [No author given]
    • FORCE. XRAYS. 2019 Mar 14.

    Related:

    Original research:

    Layers of information: interacting constraints on breast cancer risk-management by high-risk African American women.

    • Trends in Breast MRI Use Among Women with BRCA Mutations: A National Claims Analysis 2006–2016.
    • Wernli KJ, Callaway KA, Henderson LM, Kerlikowske K, Lee JM, Ross-Degnan D, Wallace JK, Wharam JF, Zhang F, Stout NK.
    • Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):624. doi: 10.1158/1055-9965.EPI-19-0079.
    • Conference abstract
    • The influence of BRCA variants of unknown significance on cancer risk management decision-making.
    • Chern JY, Lee SS, Frey MK, Lee J, Blank SV.
    • J Gynecol Oncol. 2019 Feb 27. doi: 10.3802/jgo.2019.30.e60. [Epub ahead of print]

    Related:

    Editorial:

    Clinical significance of variants of unknown significances in BRCA genes.

    • Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE).
    • Henry DA, Lee MC, Almanza D, Ahmed KA, Sun W, Boulware DC, Laronga C.
    • Breast Cancer Res Treat. 2019 Feb;174(1):39-45. doi: 10.1007/s10549-018-5057-7. Epub 2018 Nov 24.
    • Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia.
    • Hanley GE, McAlpine JN, Cheifetz R, Schrader KA, McCullum M, Huntsman D.
    • Curr Oncol. 2019 Feb;26(1):e17-e23. doi: 10.3747/co.26.4068. Epub 2019 Feb 1.
    • High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study.
    • Nilsson MP, Nilsson ED, Borg Å, Brandberg Y, Silfverberg B, Loman N.
    • Breast Cancer Res Treat. 2019 Jan;173(2):313-318. doi: 10.1007/s10549-018-5000-y. Epub 2018 Oct 11.
    • Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers.
    • Lee EG, Kang HJ, Lim MC, Park B, Park SJ, Jung SY, Lee S, Kang HS, Park SY, Park B, Joo J, Han JH, Kong SY, Lee ES.
    • Cancer Res Treat. 2019 Jan;51(1):280-288. doi: 10.4143/crt.2018.079. Epub 2018 May 4.
    • Layers of information: interacting constraints on breast cancer risk-management by high-risk African American women.
    • Padamsee TJ, Meadows R, Hils M.
    • Ethn Health. 2018 Dec 27:1-24. doi: 10.1080/13557858.2018.1562053. [Epub ahead of print]

    Related:

    Research news: Gaps in information about breast cancer risk and prevention impact African American women (FORCE. XRAYS.)

    • Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer.
    • Narod SA.
    • JAMA Oncol. 2018 Dec 1;4(12):1787-1788. doi: 10.1001/jamaoncol.2018.4931.
    • Letter, Comment

    Related:

    Original Research:

    Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.

    Letter, reply:

    Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer—Reply

    • Satisfaction and Impact on Quality of Life of Clinical and Instrumental Surveillance and Prophylactic Surgery in BRCA-mutation Carriers.
    • D'Alonzo M, Piva E, Pecchio S, Liberale V, Modaffari P, Ponzone R, Biglia N.
    • Clin Breast Cancer. 2018 Dec;18(6):e1361-e1366. doi: 10.1016/j.clbc.2018.07.015. Epub 2018 Jul 26.
    • Uptake of Preimplantation Genetic Diagnosis in Female BRCA1 and BRCA2 Mutation Carriers.
    • Mor P, Brennenstuhl S, Metcalfe KA.
    • J Genet Couns. 2018 Dec;27(6):1386-1394. doi: 10.1007/s10897-018-0264-2. Epub 2018 Jun 1.
    • Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group.
    • Nielsen SM, Eccles DM, Romero IL, Al-Mulla F, Balmaña J, Biancolella M, Bslok R, Caligo MA, Calvello M, Capone GL, Cavalli P, Chan TLC, Claes KBM, Cortesi L, Couch FJ, de la Hoya M, De Toffol S, Diez O, Domchek SM, Eeles R, Efremidis A, Fostira F, Goldgar D, Hadjisavvas A, Hansen TVO, Hirasawa A, Houdayer C, Kleiblova P, Krieger S, Lázaro C, Loizidou M, Manoukian S, Mensenkamp AR, Moghadasi S, Monteiro AN, Mori L, Morrow A, Naldi N, Nielsen HR, Olopade OI, Pachter NS, Palmero EI, Pedersen IS, Piane M, Puzzo M, Robson M, Rossing M, Sini MC, Solano A, Soukupova J, Tedaldi G, Teixeira M, Thomassen M, Tibiletti MG, Toland A, Törngren T, Vaccari E, Varesco L, Vega A, Wallis Y, Wappenschmidt B, Weitzel J, Spurdle AB, De Nicolo A, Gómez-García EB.
    • JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00091. Epub 2018 Oct 26.
    • Comparison of gynecologic cancer risk factors, incidence and mortality trends between South Korea and Israel, 1999-2013.
    • Michaan N, Park SY, Won YJ, Lim MC.
    • Jpn J Clin Oncol. 2018 Oct 1;48(10):884-891. doi: 10.1093/jjco/hyy111.
    • Risk management adherence following genetic testing for hereditary cancer syndromes: a Singaporean experience.
    • Courtney E, Chin XW, Yuen J, Li ST, Chen Y, Allen JC Jr, Tan V, Lim GH, Ngeow J.
    • Fam Cancer. 2018 Oct;17(4):621-626. doi: 10.1007/s10689-018-0071-9.
    • Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review.
    • Petelin L, Trainer AH, Mitchell G, Liew D, James PA.
    • Genet Med. 2018 Oct;20(10):1145-1156. doi: 10.1038/gim.2017.255. Epub 2018 Jan 11.
    • Review
    • Real-world health services utilisation and outcomes after BRCA1 and BRCA2 testing in Ontario, Canada: the What Comes Next Cohort Study protocol.
    • Dossa F, Cusimano MC, Sutradhar R, Metcalfe K, Little T, Lerner-Ellis J, Eisen A, Meschino WS, Baxter NN.
    • BMJ Open. 2018 Sep 4;8(9):e025317. doi: 10.1136/bmjopen-2018-025317.
    • Factors associated with breast MRI use among women with a family history of breast cancer.
    • White MC, Soman A, Weinberg CR, Rodriguez JL, Sabatino SA, Peipins LA, DeRoo L, Nichols HB, Hodgson ME, Sandler DP.
    • Breast J. 2018 Sep;24(5):764-771. doi: 10.1111/tbj.13063. Epub 2018 May 20.
    • Response to "A Psychological Perspective on Factors Predicting Prophylactic Salpingo-Oophorectomy in a Sample of Italian Women from the General Population. Results from a Hypothetical Study in the Context of BRCA Mutations".
    • Cox DM.
    • J Genet Couns. 2018 Sep;27(5):1312-1313. doi: 10.1007/s10897-018-0280-2. Epub 2018 Jul 21.
    • Letter

    Related:

    A Psychological Perspective on Factors Predicting Prophylactic Salpingo-Oophorectomy in a Sample of Italian Women from the General Population. Results from a Hypothetical Study in the Context of BRCA Mutations.

    Letter, Reply:

    Letter to the Editor: Response to Cox (2018).

    • Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
    • Kurian AW, Ward KC, Hamilton AS, Deapen DM, Abrahamse P, Bondarenko I, Li Y, Hawley ST, Morrow M, Jagsi R, Katz SJ.
    • JAMA Oncol. 2018 Aug 1;4(8):1066-1072. doi: 10.1001/jamaoncol.2018.0644.

    Related:

    Press: Multigene Sequencing Rapidly Replacing BRCA Tests. (Medscape Oncology)

    Letter, Comment:

    Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer.

    Letter, Reply:

    Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer-Reply.

    • Successful Repatriation of Breast Cancer Surveillance for High-Risk Women to the UK National Health Service Breast Screening Programme.
    • McVeigh TP, Wiggins J, Ward S, Kemp Z, George AJ.
    • Clin Breast Cancer. 2018 Aug;18(4):282-288. doi: 10.1016/j.clbc.2017.10.015. Epub 2017 Oct 28.
    • Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature.
    • Hoskins PJ.
    • Clin Oncol (R Coll Radiol). 2018 Aug;30(8):472-483. doi: 10.1016/j.clon.2018.04.004. Epub 2018 May 5.
    • Review
    • Impact of preoperative BRCA1/2 testing on surgical decision making in patients with newly diagnosed breast cancer.
    • Yadav S, Jinna S, Pereira-Rodrigues O, Reeves A, Campian S, Sufka A, Zakalik D.
    • Breast J. 2018 Jul;24(4):541-548. doi: 10.1111/tbj.13007. Epub 2018 Mar 2.
    • Uptake of risk-reducing surgery in BRCA gene carriers in Wales, UK.
    • Long J, Evans TG, Bailey D, Lewis MH, Gower-Thomas K, Murray A.
    • Breast J. 2018 Jul;24(4):580-585. doi: 10.1111/tbj.12978. Epub 2017 Dec 29.
    • Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations.
    • Kearton S, Wills K, Bunting M, Blomfield P, James PA, Burke J.
    • Fam Cancer. 2018 Jul;17(3):333-344. doi: 10.1007/s10689-017-0047-1.
    • Geographic Variation in Postoperative Imaging for Low-Risk Breast Cancer.
    • Franc BL, Copeland TP, Thombley R, Park M, Marafino B, Dean ML, Boscardin WJ, Rugo HS, Seidenwurm D, Sharma B, Johnston SR, Dudley RA.
    • J Natl Compr Canc Netw. 2018 Jul;16(7):829-837. doi: 10.6004/jnccn.2018.7024.
    • Is BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients Compared to Routine Clinical Surveillance? The Case of an Upper Middle-Income Country in Asia.
    • Lim KK, Yoon SY, Mohd Taib NA, Shabaruddin FH, Dahlui M, Woo YL, Thong MK, Teo SH, Chaiyakunapruk N.
    • Appl Health Econ Health Policy. 2018 Jun;16(3):395-406. doi: 10.1007/s40258-018-0384-8.
    • Effects of Cancer Genetic Panel Testing on at-Risk Individuals.
    • Frost AS, Toaff M, Biagi T, Stark E, McHenry A, Kaltman R.
    • Obstet Gynecol. 2018 Jun;131(6):1103-1110. doi: 10.1097/AOG.0000000000002531.
    • Risk management decisions in women with BRCA1 and BRCA2 mutations.
    • Morgan R, Brown A, Hamman KJ, Sampson J, Naik A, Massimino K.
    • Am J Surg. 2018 May;215(5):899-903. doi: 10.1016/j.amjsurg.2018.02.010. Epub 2018 Feb 13.
    • Early cancer diagnoses through BRCA1/2 screening of unselected adult biobank participants.
    • Buchanan AH, Manickam K, Meyer MN, Wagner JK, Hallquist MLG, Williams JL, Rahm AK, Williams MS, Chen ZE, Shah CK, Garg TK, Lazzeri AL, Schwartz MLB, Lindbuchler DM, Fan AL, Leeming R, Servano PO 3rd, Smith AL, Vogel VG, Abul-Husn NS, Dewey FE, Lebo MS, Mason-Suares HM, Ritchie MD, Davis FD, Carey DJ, Feinberg DT, Faucett WA, Ledbetter DH, Murray MF.
    • Genet Med. [2018 May;]20(5):554-558. doi: 10.1038/gim.2017.145. Epub 2017 Oct 26.
    • Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
    • Barrington DA, Champion ML, Boitano TKL, Walters-Haygood CL, Farmer MB, Alvarez RD, Estes JM, Leath CA 3rd.
    • Gynecol Oncol. 2018 May;149(2):337-340. doi: 10.1016/j.ygyno.2018.02.014. Epub 2018 Mar 2.
    • Results of surveillance in individuals at high-risk of pancreatic cancer: A systematic review and meta-analysis.
    • Signoretti M, Bruno MJ, Zerboni G, Poley JW, Delle Fave G, Capurso G.
    • United European Gastroenterol J. 2018 May;6(4):489-499. doi: 10.1177/2050640617752182. Epub 2018 Jan 8.
    • An iPhone Application Intervention to Promote Surveillance Among Women with a BRCA Mutation: Pre-intervention Data.
    • Cohen SA, Scherr CL, Nixon DM.
    • J Genet Couns. 2018 Apr;27(2):446-456. doi: 10.1007/s10897-018-0224-x. Epub 2018 Feb 10.
    • Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan.
    • Arai M, Yokoyama S, Watanabe C, Yoshida R, Kita M, Okawa M, Sakurai A, Sekine M, Yotsumoto J, Nomura H, Akama Y, Inuzuka M, Nomizu T, Enomoto T, Nakamura S.
    • J Hum Genet. 2018 Apr;63(4):447-457. doi: 10.1038/s10038-017-0355-1. Epub 2017 Nov 8.
    • Breast Cancer Screening Behaviors of First Degree Relatives of Women Receiving Breast Cancer Treatment and the Affecting Factors.
    • Kırca N, Tuzcu A, Gözüm S.
    • Eur J Breast Health. 2018 Jan 1;14(1):23-28. doi: 10.5152/ejbh.2017.3272. eCollection 2018 Jan.
    • A single visit multidisciplinary model for managing patients with mutations in moderate and high-risk genes in a community practice setting.
    • O'Leary MP, Goldner BS, Abboy S, Mercado PD, Plurad HY.
    • Fam Cancer. 2018 Jan;17(1):175-178. doi: 10.1007/s10689-017-0010-1.
    • Abnormal Findings Detected by Multi-modality Breast Imaging and Biopsy Results in a High-risk Clinic.
    • Laitman Y, Feldman DM, Sklair-Levy M, Yosepovich A, Barshack-Nakar I, Brodsky M, Halshtok O, Shalmon A, Gotlieb M, Friedman E.
    • Clin Breast Cancer. 2017 Dec 11. pii: S1526-8209(17)30559-1. doi: 10.1016/j.clbc.2017.12.005. [Epub ahead of print]
    • No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families.
    • Guedaoura S, Pelletier S, Foulkes WD, Hamet P, Simard J, Wong N, El Haffaf Z, Chiquette J, Dorval M.
    • Curr Oncol. 2017 Dec;24(6):352-359. doi: 10.3747/co.24.3759. Epub 2017 Dec 20.
    • Identification and management of familial breast cancer in Austria.
    • Singer CF, Tan YY, Rappaport C.
    • Horm Mol Biol Clin Investig. 2017 Nov 30;32(2). pii: /j/hmbci.2017.32.issue-2/hmbci-2017-0025/hmbci-2017-0025.xml. doi: 10.1515/hmbci-2017-0025.
    • Review
    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. Psychosocial Issues in Inherited Breast and Ovarian Cancer Syndromes. Psychosocial Aspects of Cancer Risk Management for Hereditary Breast and Ovarian Cancer. Uptake of cancer risk management options.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. Psychosocial Issues in Inherited Breast and Ovarian Cancer Syndromes. Behavioral Outcomes.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations.
    • Wahner Hendrickson AE, Bakkum-Gamez JN, J Couch F, Ghosh K, Boughey JC.
    • Ann Surg Oncol. 2017 Oct;24(11):3107-3109. doi: 10.1245/s10434-017-5999-8. Epub 2017 Jul 20.

    Related:

    Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.

    • Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
    • Gamble C, Havrilesky LJ, Myers ER, Chino JP, Hollenbeck S, Plichta JK, Kelly Marcom P, Shelley Hwang E, Kauff ND, Greenup RA.
    • Ann Surg Oncol. 2017 Oct;24(11):3116-3123. doi: 10.1245/s10434-017-5995-z. Epub 2017 Jul 11.

    Related:

    Editorial:

    Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations.

    • Differences Among a Modern Cohort of BRCA Mutation Carriers Choosing Bilateral Prophylactic Mastectomies Compared to Breast Surveillance.
    • Gilbert E, Zabor EC, Stempel M, Mangino D, Heerdt A, Pilewskie M.
    • Ann Surg Oncol. 2017 Oct;24(10):3048-3054. doi: 10.1245/s10434-017-5976-2. Epub 2017 Aug 1.
    • Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes.
    • Welsh JL, Hoskin TL, Day CN, Thomas AS, Cogswell JA, Couch FJ, Boughey JC.
    • Ann Surg Oncol. 2017 Oct;24(10):3067-3072. doi: 10.1245/s10434-017-5959-3. Epub 2017 Aug 1.
    • Multi-institutional Evaluation of Women at High Risk of Developing Breast Cancer.
    • Hermel DJ, Wood ME, Chun J, Rounds T, Sands M, Schwartz S, Schnabel FR.
    • Clin Breast Cancer. 2017 Oct;17(6):427-432. doi: 10.1016/j.clbc.2017.04.005. Epub 2017 Apr 14.
    • A Psychological Perspective on Factors Predicting Prophylactic Salpingo-Oophorectomy in a Sample of Italian Women from the General Population. Results from a Hypothetical Study in the Context of BRCA Mutations.
    • Gavaruzzi T, Tasso A, Franiuk M, Varesco L, Lotto L.
    • J Genet Couns. 2017 Oct;26(5):1144-1152. doi: 10.1007/s10897-017-0093-8. Epub 2017 Mar 23.

    Related:

    Letter:

    Response to "A Psychological Perspective on Factors Predicting Prophylactic Salpingo-Oophorectomy in a Sample of Italian Women from the General Population. Results from a Hypothetical Study in the Context of BRCA Mutations".

    Letter, Reply:

    Letter to the Editor: Response to Cox (2018).

    • BRCA Genetic Testing and Receipt of Preventive Interventions Among Women Aged 18-64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas - United States, 2009-2014.
    • Kolor K, Chen Z, Grosse SD, Rodriguez JL, Green RF, Dotson WD, Bowen MS, Lynch JA, Khoury MJ.
    • MMWR Surveill Summ. 2017 Sep 8;66(15):1-11. doi: 10.15585/mmwr.ss6615a1.
    • Screening Mammography for Women in Their 40s: The Potential Impact of the American Cancer Society and U.S. Preventive Services Task Force Breast Cancer Screening Recommendations.
    • Pitman JA, McGinty GB, Soman RR, Drotman MB, Reichman MB, Arleo EK.
    • AJR Am J Roentgenol. 2017 Sep;209(3):697-702. doi: 10.2214/AJR.16.17759. Epub 2017 May 15.
    • Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment.
    • Liede A, Mansfield CA, Metcalfe KA, Price MA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Snyder C, Lynch HT, Friedman S, Amelio J, Posner J, Narod SA, Lindeman GJ, Evans DG.
    • Breast Cancer Res Treat. 2017 Sep;165(2):433-444. doi: 10.1007/s10549-017-4332-3. Epub 2017 Jun 17.
    • Randomized Noninferiority Trial of Telephone vs In-Person Genetic Counseling for Hereditary Breast and Ovarian Cancer: A 12-Month Follow-Up.
    • Interrante MK, Segal H, Peshkin BN, Valdimarsdottir HB, Nusbaum R, Similuk M, DeMarco T, Hooker G, Graves K, Isaacs C, Wood M, McKinnon W, Garber J, McCormick S, Heinzmann J, Kinney AY, Schwartz MD.
    • JNCI Cancer Spectr. 2017 Sep;1(1):pkx002. doi: 10.1093/jncics/pkx002. Epub 2017 Sep 22.
    • Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.
    • Cragun D, Weidner A, Lewis C, Bonner D, Kim J, Vadaparampil ST, Pal T.
    • Cancer. 2017 Jul 1;123(13):2497-2505. doi: 10.1002/cncr.30621. Epub 2017 Feb 9.
    • Practice Patterns of Hereditary Ovarian Cancer Management in Korea.
    • Choi MC, Lim MC, Lee M, Kim MK, Suh DH, Song YJ, Kim TJ, Chang SJ, Kim JW.
    • Int J Gynecol Cancer. 2017 Jun;27(5):895-899. doi: 10.1097/IGC.0000000000000964.
    • Influence of the Angelina Jolie Announcement and Insurance Reimbursement on Practice Patterns for Hereditary Breast Cancer.
    • Lee J, Kim S, Kang E, Park S, Kim Z, Lee MH; Korean Breast Cancer Society.
    • J Breast Cancer. 2017 Jun;20(2):203-207. doi: 10.4048/jbc.2017.20.2.203. Epub 2017 Jun 26.
    • Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.
    • Johns D, Agarwal J, Anderson L, Ying J, Kohlmann W.
    • J Womens Health (Larchmt). 2017 Jun;26(6):702-706. doi: 10.1089/jwh.2016.5931. Epub 2016 Dec 6.
    • Screening Breast MRI Outcomes in Routine Clinical Practice: Comparison to BI-RADS Benchmarks.
    • Strigel RM, Rollenhagen J, Burnside ES, Elezaby M, Fowler AM, Kelcz F, Salkowski L, DeMartini WB.
    • Acad Radiol. 2017 Apr;24(4):411-417. doi: 10.1016/j.acra.2016.10.014. Epub 2016 Dec 13.
    • Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history.
    • Skandarajah AR, Thomas S, Shackleton K, Chin-Lenn L, Lindeman GJ, Mann GB.
    • Breast. 2017 Apr;32:93-97. doi: 10.1016/j.breast.2017.01.002. Epub 2017 Jan 18.
    • Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.
    • Mai PL, Piedmonte M, Han PK, Moser RP, Walker JL, Rodriguez G, Boggess J, Rutherford TJ, Zivanovic O, Cohn DE, Thigpen JT, Wenham RM, Friedlander ML, Hamilton CA, Bakkum-Gamez J, Olawaiye AB, Hensley ML, Greene MH, Huang HQ, Wenzel L.
    • Gynecol Oncol. 2017 Apr;145(1):122-129. doi: 10.1016/j.ygyno.2017.02.008. Epub 2017 Feb 10.
    • The effect of a celebrity health disclosure on demand for health care: trends in BRCA testing and subsequent health services use.
    • Roberts MC, Dusetzina SB.
    • J Community Genet. 2017 Apr;8(2):141-146. doi: 10.1007/s12687-017-0295-7. Epub 2017 Mar 15.
    • Decision making for breast cancer prevention among women at elevated risk.
    • Padamsee TJ, Wills CE, Yee LD, Paskett ED.
    • Breast Cancer Res. 2017 Mar 24;19(1):34. doi: 10.1186/s13058-017-0826-5.
    • Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation.
    • Buchanan AH, Voils CI, Schildkraut JM, Fine C, Horick NK, Marcom PK, Wiggins K, Skinner CS.
    • J Genet Couns. 2017 Feb;26(1):79-92. doi: 10.1007/s10897-016-9981-6. Epub 2016 Jun 6.
    • Do celebrity endorsements matter? Observational study of BRCA gene testing and mastectomy rates after Angelina Jolie's New York Times editorial.
    • Desai S, Jena AB.
    • BMJ. 2016 Dec 14;355:i6357. doi: 10.1136/bmj.i6357.

    Related:

    Research News:

    Angelina Jolie's mastectomy triggered sharp rise in gene testing.

    Research News: Angelina Jolie spoke out on BRCA testing: Did genetic testing increase? (FORCE)

    Blog post: "Angelina Jolie Effect”: What Should I Know About Hereditary Cancer and Testing? (NSGC Blog)

    Research News: Were women foolish to follow Angelina Jolie into BRCA cancer gene testing? (STAT)

    Research News: Jolie Effect: BRCA Tests Up but No Change in Mastectomy. (Medscape)

    • A Dedicated Follow-Up Clinic for BRCA Mutation Carriers.
    • Yerushalmi R, Rizel S, Zoref D, Sharon E, Eitan R, Sabah G, Grubstein A, Rafson Y, Cohen M, Magen A, Birenboim I, Margel D, Ozlavo R, Sulkes A, Brenner B, Perry S.
    • Isr Med Assoc J. 2016 Sep;18(9):549-552.

    Related:

    Editorial:

    Handling Individuals with High Cancer Risk: One Size Doesn't Fit All.

    • Adherence to the breast cancer surveillance program for women at risk for familial breast and ovarian cancer versus overscreening: a monocenter study in Germany.
    • Vetter L, Keller M, Bruckner T, Golatta M, Eismann S, Evers C, Dikow N, Sohn C, Heil J, Schott S.
    • Breast Cancer Res Treat. 2016 Apr;156(2):289-99. doi: 10.1007/s10549-016-3748-5. Epub 2016 Mar 9.
    • Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
    • Podo F, Santoro F, Di Leo G, Manoukian S, de Giacomi C, Corcione S, Cortesi L, Carbonaro LA, Trimboli RM, Cilotti A, Preda L, Bonanni B, Pensabene M, Martincich L, Savarese A, Contegiacomo A, Sardanelli F.
    • Clin Cancer Res. 2016 Feb 15;22(4):895-904. doi: 10.1158/1078-0432.CCR-15-0459. Epub 2015 Oct 26.
    • Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations.
    • Robinson LS, Hendrix A, Xie XJ, Yan J, Pirzadeh-Miller S, Pritzlaff M, Read P, Pass S, Euhus D, Ross TS.
    • EBioMedicine. 2015 Oct 21;2(11):1827-33. doi: 10.1016/j.ebiom.2015.10.022. eCollection 2015.

    Related:

    Commentary

    Differences in Uptake of Risk Reduction Strategies Among Underserved Populations.

    • Comparison of risk management strategies between women testing positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations.
    • Garcia C, Lyon L, Littell RD, Powell CB.
    • Genet Med. 2014 Dec;16(12):896-902. doi: 10.1038/gim.2014.48. Epub 2014 May 22.
    • Attitudes and compliance of clinical management after genetic testing for hereditary breast and ovarian cancer among high-risk Southern Chinese females with breast cancer history.
    • Kwong A, Chu AT, Wu CT, Tse DM.
    • Fam Cancer. 2014 Sep;13(3):423-30. doi: 10.1007/s10689-014-9706-7.
    • Disclosure Pattern and Follow-Up After the Molecular Diagnosis of BRCA/CHEK2 Mutations.
    • Kegelaers D, Merckx W, Odeurs P, van den Ende J, Blaumeiser B.
    • J Genet Couns. 2014 Apr;23(2):254-61. doi: 10.1007/s10897-013-9656-5. Epub 2013 Oct 11.
    • Risk management options elected by women after testing positive for a BRCA mutation.
    • Garcia C, Wendt J, Lyon L, Jones J, Littell RD, Armstrong MA, Raine-Bennett T, Powell CB.
    • Gynecol Oncol. 2014 Feb;132(2):428-33. doi: 10.1016/j.ygyno.2013.12.014. Epub 2013 Dec 16.
    • The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers.
    • Borreani C, Manoukian S, Bianchi E, Brunelli C, Peissel B, Caruso A, Morasso G, Pierotti M.
    • Clin Genet. 2014 Jan;85(1):7-15. doi: 10.1111/cge.12298. Epub 2013 Nov 5.
    • Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers.
    • Pal T, Lee JH, Besharat A, Thompson Z, Monteiro A, Phelan C, Lancaster J, Metcalfe K, Sellers T, Vadaparampil S, Narod S.
    • Clin Genet. 2014 Jan;85(1):49-53. doi: 10.1111/cge.12130. Epub 2013 Mar 21.
    • Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria.
    • Singer C, Muhr D, Rappaport C, Tea MK, Gschwantler-Kaulich D, Fink-Retter A, Pfeiler G, Berger A, Sun P, Narod S.
    • Clin Genet. 2014 Jan;85(1):72-5. doi: 10.1111/cge.12216. Epub 2013 Jul 16.
    • Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers.
    • Collins IM, Milne RL, Weideman PC, McLachlan SA, Friedlander ML, Kathleen Cuningham Foundation Consortium For Research Into Familial Breast Cancer KC, Hopper JL, Phillips KA.
    • Med J Aust. 2013 Nov 18;199(10):680-3.
    • Patterns of breast cancer surveillance and breast cancer detection in women with serous ovarian/tubal or peritoneal carcinomas who have had brca mutation testing.
    • Daniel Paik, Farin Amersi, Alexandra Gangi, Catherine Dang, Beth Karlan, Ronald Leuchter, Andrew Li, Christine Walsh, B.J. Rimel, Ilana Cass.
    • Gynecologic Oncology. 2013 Oct;131(1):264. doi: 10.1016/j.ygyno.2013.07.046.
    • Conference abstract
    • Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis.
    • Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, Tilanus-Linthorst MM, Koppert LB, Obdeijn IM, van Deurzen CH, Collée JM, Seynaeve C, Hooning MJ.
    • Ann Oncol. 2013 Aug;24(8):2029-35. doi: 10.1093/annonc/mdt134. Epub 2013 Apr 10.
    • Genetic Counseling, Cancer Screening, Breast Cancer Characteristics, and General Health among a Diverse Population of BRCA Genetic Testers.
    • Beattie MS, Copeland K, Fehniger J, Cheung E, Joseph G, Lee R, Luce J.
    • J Health Care Poor Underserved. [2013 Aug;]24(3):1150-66. doi: 10.1353/hpu.2013.0151.
    • Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing.
    • Mannis GN, Fehniger JE, Creasman JS, Jacoby VL, Beattie MS.
    • JAMA Intern Med. 2013 Jan 28;173(2):96-103. doi: 10.1001/2013.jamainternmed.962.

    Related:

    Comment:

    Role of genetic testing for screening and prevention for ovarian cancer: comment on "Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing".

    • Role of genetic testing for screening and prevention for ovarian cancer: comment on "Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing".
    • Grann V, Ashby-Thompson M.
    • JAMA Intern Med. 2013 Jan 28;173(2):103-4. doi: 10.1001/jamainternmed.2013.2729.

    Related:

    Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing.

    • Breast MRI Use Uncommon among U.S. Women.
    • Miller JW, Sabatino SA, Thompson TD, Breen N, White MC, Ryerson AB, Taplin S, Ballard-Barbash R.
    • Cancer Epidemiol Biomarkers Prev. 2013 Jan;22(1):159-66. doi: 10.1158/1055-9965.EPI-12-0967. Epub 2012 Nov 15.
    • Compliance with screening recommendations according to breast cancer risk levels in Izmir, Turkey.
    • Acikgoz A, Ergor G.
    • Asian Pac J Cancer Prev. 2013;14(3):1737-42.
    • BRCA1/2 testing and cancer risk management in underserved women at a public hospital.
    • Hamann HA, Robinson LD, Moldrem AW, Golden EP, Mook JA, Pechero Bishop W, Sugg Skinner C, Euhus DM.
    • Commun Oncol 2012 Dec;9(12):369-376.
    • Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening.
    • Metcalfe KA, Mian N, Enmore M, Poll A, Llacuachaqui M, Nanda S, Sun P, Hughes KS, Narod SA.
    • Breast Cancer Res Treat. 2012 Jun;133(2):735-40. doi: 10.1007/s10549-011-1941-0. Epub 2012 Jan 13.
    • Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.
    • Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, Finch C, Kelly S, Taylor KL, Perley L.
    • Cancer. 2012 Jan 15;118(2):510-7. doi: 10.1002/cncr.26294. Epub 2011 Jun 29.
    • Breast cancer risk assessment in 64,659 women at a single high-volume mammography clinic.
    • Brinton JT, Barke LD, Freivogel ME, Jackson S, O'Donnell CI, Glueck DH.
    • Acad Radiol. 2012 Jan;19(1):95-9. doi: 10.1016/j.acra.2011.09.003. Epub 2011 Nov 3.